These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 32576444

  • 1. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
    Chen X, Zhao G, Zhong P, Zhang M, Chen R, Zhang D.
    Clin Lung Cancer; 2020 Nov; 21(6):e564-e566. PubMed ID: 32576444
    [No Abstract] [Full Text] [Related]

  • 2. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J, Gu D, Lu H, Liu S, Kong J.
    J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z, Wu X, Ma S, Zhang C, Zhang Z, Wang S, Yu S, Wang Q.
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X, Wang W, Zou B, Li Y, Yang X, Liu N, Ma Q, Zhang X, Wang Y, Li D.
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G, Pajor G, Szuhai K, Morreau H, Kocsmár I, Kocsmár É, Pajor L, Kajtár B, Sárosi V, Lotz G, Tornóczky T.
    Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
    [Abstract] [Full Text] [Related]

  • 11. Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
    Wang L, Li L, Zhou X, Zhang D.
    Lung Cancer; 2024 May; 191():107797. PubMed ID: 38669726
    [No Abstract] [Full Text] [Related]

  • 12. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.
    Dai S, Liu XQ, Wu Q, Du CM, Liu Q, Xue YY, Luo F, Li Y.
    Lung Cancer; 2023 Jan; 175():121-124. PubMed ID: 36495785
    [Abstract] [Full Text] [Related]

  • 13. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M, Wang Q, Ding Y, Wang G, Chu Y, He X, Wu X, Shao YW, Lu K.
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
    Zeng L, Xia C, Zhang Y, Yang N.
    J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
    Guo J, Shi J, Yao M, Jin Y, Liu D, Liu W, Wang K, Jiang D.
    Medicine (Baltimore); 2020 Nov 06; 99(45):e22631. PubMed ID: 33157918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.